You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
McKinsey
Mallinckrodt
Merck
AstraZeneca

Last Updated: January 17, 2021

DrugPatentWatch Database Preview

RAPIVAB Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Rapivab, and what generic alternatives are available?

Rapivab is a drug marketed by Biocryst and is included in one NDA. There are three patents protecting this drug.

This drug has sixty-one patent family members in twenty-eight countries.

The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the peramivir profile page.

US ANDA Litigation and Generic Entry Outlook for Rapivab

Rapivab was eligible for patent challenges on December 19, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 16, 2023. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Summary for RAPIVAB
Drug patent expirations by year for RAPIVAB
Drug Prices for RAPIVAB

See drug prices for RAPIVAB

Generic Entry Opportunity Date for RAPIVAB
Generic Entry Date for RAPIVAB*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for RAPIVAB

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
BioCryst PharmaceuticalsPhase 3
Johns Hopkins UniversityPhase 4
Department of Health and Human ServicesPhase 4

See all RAPIVAB clinical trials

US Patents and Regulatory Information for RAPIVAB

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
AstraZeneca
McKinsey
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.